RT @IHSMarkit: "If you want to take care of shareholders, you better take care of your people, and you better take care of your planet, and…
Drug patent expirations 2014
2014 is shaping up to be among the quietest years in recent memory as the patent cliff reaches its end - although there will be a notable spike again in major drugs going off-patent in 2015. For the year ahead, Merck & Co is most exposed to patent expirations. A series of drugs will lose their exclusivity in either the US or Europe, including major products like Temodar, Avelox and Remicade. There will be significant activity in Europe this year with a series of interesting patent expirations. Most notable will be Sanofi's Lantus (insulin glargine), where there is a potential for Lilly to enter the biosimilar market by the end of the year. Similarly, patents for key drugs that have driven a significant portion of biopharmaceutical growth in the last ten years - including Herceptin, Rituxan and Remicade - expire in Europe this year.
- The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September
- Is the US ready to start relaxing COVID-19 lockdowns?
- COVID-19 could cause delays for price framework agreements in parts of Europe
- US scrambles for resources in COVID-19 response
- COVID-19: Risk of severe complications among the United States health workforce
- COVID-19 pandemic: Health system surge capacity
- UK bans parallel export of two COVID-19 treatment candidates to protect national supply
- China’s young biosimilars sector
The race intensifies for a COVID-19 vaccine as hope builds for emergency approval by September https://t.co/9fX4R1K8rC